Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Amphastar Pharmaceuticals Inc. (AMPH) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 1,761 employees
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Total Value
-$6,830,984.50
Total Shares
281,977
Average Trade Value
-$145,340.10
Most Active Insider
Zhang Jack Y.
Total Activity: $19,352,223
Largest Single Transaction
$6,032,758
by Zhang Jack Y. on Mar 14, 2025
30-Day Activity
1 Transaction
Volume: 500 shares
Value: $14,190
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Apr 1, 2025 | 500 | $14,190 | 73,909 (-0.7%) | Sale | ||
Cfo, EVP Treasurer
|
Mar 17, 2025 | 3,004 | $83,181 | 125,258 (-2.4%) | Payment of Exercise Price | |
EVP Corp Admin Center
|
Mar 17, 2025 | 1,731 | $47,931 | 90,909 (-1.9%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 17, 2025 | 16,150 | $447,194 | 2,647,659 (-0.6%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 17, 2025 | 7,223 | $200,005 | 1,185,475 (-0.6%) | Payment of Exercise Price | |
Senior Evp, Production Center
|
Mar 17, 2025 | 1,967 | $54,466 | 137,497 (-1.4%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 15, 2025 | 9,765 | $260,335 | 2,663,809 (-0.4%) | Payment of Exercise Price | |
Cfo, EVP Treasurer
|
Mar 15, 2025 | 1,968 | $52,467 | 128,262 (-1.5%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 15, 2025 | 4,115 | $109,706 | 1,192,698 (-0.3%) | Payment of Exercise Price | |
Senior Evp, Production Center
|
Mar 15, 2025 | 1,222 | $32,579 | 139,464 (-0.9%) | Payment of Exercise Price | |
EVP Corp Admin Center
|
Mar 15, 2025 | 1,031 | $27,486 | 92,640 (-1.1%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 14, 2025 | 162,657 | $4,336,436 | 1,196,813 (-13.6%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 14, 2025 | 226,285 | $6,032,758 | 2,673,574 (-8.5%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 14, 2025 | 290,477 | $4,267,107 | 2,899,859 (+10.0%) | Exercise/Conversion | |
CEO Chief Scientific Officer
|
Mar 14, 2025 | 211,213 | $3,102,719 | 1,359,470 (+15.5%) | Exercise/Conversion | |
EVP Corp Admin Center
|
Mar 10, 2025 | 20,837 | $10,000 | 93,671 (+22.2%) | Grant | |
CEO Chief Scientific Officer
|
Mar 10, 2025 | 116,226 | $10,000 | 2,609,382 (+4.5%) | Grant | |
Senior Evp, Production Center
|
Mar 10, 2025 | 24,692 | $10,000 | 140,686 (+17.6%) | Grant | |
CEO Chief Scientific Officer
|
Mar 10, 2025 | 48,996 | $0 | 1,148,257 (+4.3%) | Grant | |
Cfo, EVP Treasurer
|
Mar 10, 2025 | 36,747 | $10,000 | 130,230 (+28.2%) | Grant | |
Cfo, EVP Treasurer
|
Mar 6, 2025 | 2,141 | $60,633 | 93,483 (-2.3%) | Payment of Exercise Price | |
Mar 6, 2025 | 1,000 | $27,986 | 74,409 (-1.3%) | Sale | ||
CEO Chief Scientific Officer
|
Mar 6, 2025 | 3,069 | $86,914 | 1,099,261 (-0.3%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 6, 2025 | 9,645 | $273,146 | 2,493,156 (-0.4%) | Payment of Exercise Price | |
EVP Corp Admin Center
|
Mar 6, 2025 | 1,141 | $32,313 | 72,834 (-1.6%) | Payment of Exercise Price | |
Senior Evp, Production Center
|
Mar 6, 2025 | 1,354 | $38,345 | 115,994 (-1.2%) | Payment of Exercise Price | |
Cfo, EVP Treasurer
|
Mar 4, 2025 | 7,490 | $99,992 | 101,594 (+7.4%) | Exercise/Conversion | |
Cfo, EVP Treasurer
|
Mar 4, 2025 | 4,231 | $116,515 | 97,363 (-4.3%) | Sale | |
Cfo, EVP Treasurer
|
Mar 4, 2025 | 1,739 | $48,031 | 95,624 (-1.8%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 4, 2025 | 2,426 | $67,006 | 1,102,330 (-0.2%) | Payment of Exercise Price | |
Senior Evp, Production Center
|
Mar 4, 2025 | 1,121 | $30,962 | 117,348 (-1.0%) | Payment of Exercise Price | |
CEO Chief Scientific Officer
|
Mar 4, 2025 | 5,753 | $158,898 | 2,502,801 (-0.2%) | Payment of Exercise Price | |
EVP Corp Admin Center
|
Mar 4, 2025 | 963 | $26,598 | 73,975 (-1.3%) | Payment of Exercise Price | |
Senior Evp, Production Center
|
Dec 13, 2024 | 8,000 | $90,640 | 126,469 (+6.3%) | Exercise/Conversion | |
Senior Evp, Production Center
|
Dec 13, 2024 | 8,000 | $361,840 | 118,469 (-6.8%) | Sale | |
Senior Evp, Production Center
|
Dec 12, 2024 | 7,000 | $310,975 | 118,469 (-5.9%) | Sale | |
Senior Evp, Production Center
|
Dec 12, 2024 | 7,000 | $79,310 | 125,469 (+5.6%) | Exercise/Conversion | |
Dec 9, 2024 | 10,000 | $437,702 | 30,471 (-32.8%) | Sale | ||
Dec 9, 2024 | 10,000 | $195,200 | 40,471 (+24.7%) | Exercise/Conversion | ||
Nov 12, 2024 | 5,000 | $243,986 | 31,471 (-15.9%) | Sale | ||
Nov 12, 2024 | 2,500 | $41,725 | 36,471 (+6.9%) | Exercise/Conversion | ||
Senior Evp, Production Center
|
Nov 12, 2024 | 6,893 | $103,050 | 125,281 (+5.5%) | Exercise/Conversion | |
Senior Evp, Production Center
|
Nov 12, 2024 | 6,893 | $336,930 | 118,388 (-5.8%) | Sale | |
EVP Corp Admin Center
|
Nov 6, 2024 | 5,214 | $271,389 | 74,938 (-7.0%) | Sale | |
EVP Corp Admin Center
|
Nov 6, 2024 | 5,214 | $67,938 | 80,152 (+6.5%) | Exercise/Conversion | |
Cfo, EVP Treasurer
|
Nov 6, 2024 | 7,426 | $386,523 | 94,103 (-7.9%) | Sale | |
Cfo, EVP Treasurer
|
Nov 6, 2024 | 7,426 | $96,761 | 101,529 (+7.3%) | Exercise/Conversion |